Patents by Inventor Beatriz Moreno Bruna

Beatriz Moreno Bruna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synergistic 5?-methylthioadenosine combinations
    Patent number: 8236778
    Abstract: The present invention relates to combinations of 5?-methylthioadenosine and glatiramer acetate, and to their use in the treatment of multiple sclerosis. In a particular embodiment, the present invention relates to a product comprising 5?-methylthioadenosine and glatiramer acetate as a combined preparation for the simultaneous, separate, or sequential use thereof for the prevention and/or treatment of multiple sclerosis.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: August 7, 2012
    Assignee: Proyecto de Biomedicina Cima, S.L.
    Inventors: Matías Antonio Ávila Zaragozá, Fernando José Corrales Izquierdo, Begoña Fernández Díez, Beatriz Moreno Bruna, Pablo Villoslada Díaz
  • SYNERGISTIC 5'-METHYLTHIOADENOSINE COMBINATIONS
    Publication number: 20110015132
    Abstract: The present invention relates to combinations of 5?-methylthioadenosine and glatiramer acetate, and to their use in the treatment of multiple sclerosis. In a particular embodiment, the present invention relates to a product comprising 5?-methylthioadenosine and glatiramer acetate as a combined preparation for the simultaneous, separate, or sequential use thereof for the prevention and/or treatment of multiple sclerosis.
    Type: Application
    Filed: March 18, 2009
    Publication date: January 20, 2011
    Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.
    Inventors: Matias Antonio Ávila Zaragozá, Fernando José Corrales Izquierdo, Begona Fernández Díez, Beatriz Moreno Bruna, Pablo Villoslada Díaz
  • Use of 5?-methylthioadenosine (MTA) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection
    Patent number: 7820637
    Abstract: 5?-methylthioadenosine (MTA), its pharmaceutically acceptable salts and/or prodrugs may be used in the prevention and/or treatment of autoimmune diseases, such as, for example, Multiple Sclerosis (MS), as well as in the prevention and/or treatment of transplant rejection.
    Type: Grant
    Filed: March 17, 2005
    Date of Patent: October 26, 2010
    Assignee: Proyecto de Biomedicina Cima, S.L.
    Inventors: Pablo Villoslada Díaz, Matías Ávila Zaragoza, Beatriz Moreno Bruna, Fernando Corrales Izquierdo, Carmen Berasain Lasarte, Elena Ruiz García-Trevijano
  • USE OF 5'-METHYLTHIOADENOSINE (MTA) IN THE PREVENTION AND/OR TREATMENT OF AUTOIMMUNE DISEASES AND/OR TRANSPLANT REJECTION
    Publication number: 20090042831
    Abstract: 5?-methylthioadenosine (MTA), its pharmaceutically acceptable salts and/or prodrugs may be used in the prevention and/or treatment of autoimmune diseases, such as, for example, Multiple Sclerosis (MS), as well as in the prevention and/or treatment of transplant rejection.
    Type: Application
    Filed: March 17, 2005
    Publication date: February 12, 2009
    Applicant: Proyecto de Biomedicina Cima, S.L.
    Inventors: Pablo Villoslada Diaz, Matias Avila Zaragoza, Beatriz Moreno Bruna, Fernando Corrales Izquierdo, Carmen Berasain Lasarte, Elena Ruiz Garcia-Trevijano
  • Bacterial adpglucose pyrophospatase method for obtaining the latter and its use in the production of assay devices and in the obtention of transgenic plants and bacteria
    Publication number: 20050181473
    Abstract: Bacterial ADPglucose pyrophosphatase, method of production, use in the manufacture of testing devices and in the production of transgenic plants and bacteria. AGPPase is an enzyme that catalyzes the hydrolysis of ADPG (adenosine diphosphate glucose). The enzyme obtained from microbial extracts is used in testing devices for determining levels of ADPG, based on the G1P (glucose-1-phosphate) released by the reaction catalyzed by AGPPase. Partial amino acid sequences of the enzyme, the sequence of the gene that codes for it and the derived protein are also described. Finally, the production of transgenic plants and bacteria that overexpress the gene of AGPPase is described. The bacteria do not accumulate glycogen, whereas the plants obtained possess a high content of soluble sugars, low starch content and high resistance to high concentrations of salts and to high temperatures.
    Type: Application
    Filed: April 10, 2002
    Publication date: August 18, 2005
    Inventors: Javier Pozueta Romero, Edurne Baroja Fernandez, Francisco Munoz Perez, Beatriz Moreno Bruna, Aitor Zandueta Criado, Milagros Rodriguez Lopez, Ainara Bastarrica Berasategui, Maria Moran Zorzano